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ABSTRACT 
The oral route is most familiar route as it has low cost of therapy and helps in the ease of administration of therapeutic agents which lead to high 
levels of patient compliance. The most known oral solid dosage forms are tablets and capsules. Many patients’ particularly pediatric and geriatric 
patients find it difficult to swallow tablets and hard gelatin capsules and do not take their medicines as prescribed. Difficulty in swallowing or 
dysphagia is identified to afflict nearly 35% of the general population. To reduce these difficulties, the growth of several fast dissolving drug 
delivery systems has been produced. Oral dissolving film is relatively a new dosage form in which thin film is prepared using hydrophilic 
polymers, which rapidly dissolves on tongue or buccal cavity. The film overcomes the danger/fear of choking. An ideal film should have the 
characteristics like pleasant taste, high stability, ease of handling and administration, no water necessary for administration. The present review 
focuses on hydrophilic polymers, plasticizers, sweeteners, flavors and colors etc which are used in the formulation of oral dissolving films 
including the manufacturing  aspects of oral dissolving film like solvent casting method, rolling method, extrusion method and solid dispersion 
method and evaluation parameters like disintegration, dissolution, tensile strength, thickness, folding endurance, elastic modulus for oral 
dissolving films. 
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I. INTRODUCTION  
In solid dosage forms, some patients have major problem in 
the use of tablets was swallowing or chewing which forms 
risk or fear of chocking. In the oral delivery of drug, oral 
dissolving film is a new drug delivery system. Oral film a type 
of film which is utilized in severe condition such as pain, 
antiemetic, anti-migraine, anti-hypertension, congestive 
heart failure, and Asthma etc. Oral dissolving film has 
attained popularity due to its availability in various size and 
shape 1. Oral dissolving films are meant to disintegrate or 
dissolve within seconds. They provide advantages like 
administration without water, rapid onset of action and 
convenience of dosing. For fast dissolving dosage forms, 
active pharmaceutical ingredients absorption is feasible 
through the oral mucosa and may improve bioavailability 2. 
II. The concept of oral dissolving film (ODF) 
 This delivery system composed of a thin film. 
 After keeping it on the top of the tongue, the film 
dissolves within seconds, promoting first pass 
metabolism as estimated to tablet and other immediate 
release oral solid dosage forms, and may enhance the 
bioavailability of drug 3. 
 ODF dissolves in the mouth like a cotton candy. 
III. The benefits of oral dissolving film (ODF) 
when compared with fast dissolving film 
(FDT) 
 Accessibility of larger surface area that drives to faster 
disintegration and dissolution in the oral cavity within 
seconds 4. 
 During transportation and storing of ODF, they don’t 
need any kind of special protection as they are flexible 
when compared with fast dissolving tablets as they are 
fragile. 
 Among dysphasic patients, negative requirement of 
water had led to satisfactory results for ODF. 
 Usage of ODF gives no fear of chocking when compared 
with fast dissolving tablets. 
 The considerable surface area present in the film dosage 
form gives rapid wetting by saliva and quickly 
disintegrates which dissolve and absorbed directly and 
can enter the systemic circulation without undergoing 
first-pass hepatic metabolism and on enhancement the 
bioavailability 5. 
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 As per convenience of the individual, the dosage form 
can be consumed at any place and any time. 
 The first pass effect can be ignored, so a decrease in the 
dose which can guide to reduction in side effects 
associated with the molecule 6. 
 Patients suffering from dysphagia, repeated emesis, 
hypertension, heart attack, asthma, motion sickness, 
paralysis and mental disorders favor this dosage form 
as they are not capable to swallow large quantities of 
water. 
IV. Formulation of oral dissolving films: 
The oral dissolving films composition is given in table 1. 
 
Table 1: Composition of Fast Dissolving Film 7, 8 
S.No Ingredients Amount(w/w) 
A.  Active Pharmaceutical ingredients 5 to 30 % 
B.  Water soluble polymer / Film forming polymer 45 % 
C.  Plasticizer 0 to 20 % 
D.  Strip forming polymers  15 % 
E.  Saliva stimulating agent 2 to 6 % 
F.  Surfactant q.s 
G.  Sweetening agent 3 to 6 % 
H.  Flavours, colors, fillers q.s 
 
A. Active Pharmaceutical Ingredient 
The area of drug loaded film should be between 1-20 cm2 
which depends on the amount of water-soluble polymers 
that are responsible for faster disintegration. The oral strip 
technology has the potential to deliver different variety of 
APIS. A number of molecules can be incorporated into this 
delivery system. They may contain cough/cold remedies 
(antitussives, expectorants), anxiety drugs, cardiovascular 
agents, sore throat, erectile dysfunction drugs, anti-
histamines, anti-asthmatics, gastrointestinal disorders, 
nausea, pain, CNS (e.g. anti-parkinson’s disease). Other 
applications contain caffeine strips, snoring aid, 
multivitamins, sleeping aid etc. As the size of dosage form 
has limitation, high dose molecules are difficult to administer 
in oral strip. Generally 5%w/w to 30%w/w of active 
pharmaceutical ingredients can be administered in oral strip. 
It is always useful to have micronized API which will 
enhance the texture of the film and also for better dissolution 
and uniformity in the oral strip. In these oral strip 
technologies, APIs are more potential and have bitter taste. 
This forms the formulation unpalatable mainly for pediatric 
preparations. Thus, before administering the API in the oral 
strip, the taste should be masked. Various approaches can be 
used to improve the palatability of the combination. Certain 
pathologies need instantaneous release of the medicament 
for prompt relief. For instance, in the case of migraine 
enhanced clinical effect is desired by the individual. 
Regiospecific delivery of the medicament would be needed in 
the case of sore throat, cough, allergy and other local oral 
manifestations. Some of the examples of suitable drug 
molecule that can be administered in the oral strip are listed 
in following table 3. 
 
Table 3: Examples of Suitable Drug Molecule that can be Incorporated in Oral Strip 
Molecule Therapeutic Category Dose 
Chlorpheneramine maleate Anti-allergic 4mg 
Zolmitriptan Anti-migraine 2.5mg 
Cetrizine Anti-histaminic 5 to 10mg 
Famotidine Antacid 10mg 
Loperamide Anti-diarrhoeal 2mg 
Ketoprfen Analgesic 12.5mg 
Dicyclomine Muscle relaxant 25mg 
Nicotine Smoking cessation 1 to 15mg 
Omeprazole Proton pump inhibitor 10 to 20mg 
 
B. Film Forming Polymers 
Water soluble polymers are utilized such as HPMC E-3, E-5 
E-15, K-3., Methyl cellulose A-3, A-6 and A-6, 
Carboxymethylcellulose, pullulan, maltodextrin, 
hydroxypropylcellulose cekol 30, polyvinyl alcohol etc. for 
the preparation of the oral soluble film. They can be utilized 
individually and also in combination, to impact the desired 
properties into the film. 
The characteristic properties of the film forming polymer 
o It must have good shelf life. 
o It must have good wetting property. 
o It shall have good spread ability property. 
o It must not aid in cause secondary infections in the oral 
mucosa/ dental region. 
o It must have a good mouth feel property. 
o Polymer employed must be non-toxic, non-irritant and 
devoid of leach able impurities. 
C. Plasticizers 
It is an essential ingredient in oral film as it imparts 
flexibility to the film by reducing its brittleness and improves 
the strip property for preparing the oral film. It also 
improves the flow of polymer and enhances the strength of 
the polymer. The selection of plasticizer will rely upon its 
compatibility with the polymer and also solvent employed in 
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the casting of the strip. Plasticizers are frequently used in the 
concentration of 0-20%w/w of dry polymer weight. 
D. Strip Forming Polymers 
The polymers in the formulation can be used alone are in 
combination to obtain the desired strip properties. The film 
obtained should be tough enough so that they won’t be any 
damage while handling or during transportation. The 
robustness of the strip will rely upon the type of polymer 
and its amount. A variety of polymers are available for the 
preparation of oral strip. On the other side, fast dissolving 
strip dosage form must have the ability to disintegrate in 
seconds when placed in mouth and deliver the drug to the 
oral cavity instantaneously. Various polymers used in the 
formulation of oral strips are given in table 2 .Of the various 
polymers available pullulan, gelatin and hydromellose are 
most commonly used for preparation of oral strip. Atleast 
45% w/w of polymers should generally be present based on 
the total weight of dry oral strip. 
  
Table 2: Strip Forming Polymers 
Strip 
Forming 
Polymers 
Hydroxyl propyl 
methyl cellulose 
(hypromellose) 
Hydroxyl 
propyl 
cellulose 
Starch and 
modified 
starch 
Pullulan Gelatin 
Carboxymethyl 
cellulose 
Synonym 
HPMC, methocel, 
metolose, benecel. 
Hydroxy 
prpoply ether, 
hyprolose, 
klucel, Nisso 
HPC 
Amido, amylum, 
pharmGel, 
fluftex W, 
Instant pure-
Cote,Melogel 
Pullulan,1,6α 
linked 
maltotriose 
Byco, cryogel, 
instgel, solugel 
Akulell, blanose, 
aquasorb, 
CMCsodium 
Molecular 
weight 
10000-1,500,000 
50000-
1,250,000 
50,000-1,60,000 8000-2,000,000 15,000-2,50,000 90,000-7,00,000 
Solubility 
Soluble in cold 
water, forming a 
viscous colloidal 
solution, in soluble 
in chloroform, 
ethane 
It is freely 
soluble in 
water below 
380C forming a 
smooth, clear, 
colloidal 
solution 
Starch is 
insoluble in cold 
water and 
ethanol. It swells 
in water by 
about 5 to 10% 
at 370C 
It is soluble in 
hot as well as 
cold water 
Soluble in 
glycerin, acid and 
alkali. Swells in 
water and 
softens. It is 
soluble in hot 
water. 
It is easily dispersed 
in water to form a 
clear or colloidal 
solution 
Film 
forming 
ability 
It has a film 
forming ability in 2 
to 20% w/w 
concentration 
5%w/w 
solution is 
generally used 
for film coating 
Modified 
starches have a 
property to form 
quick dissolving 
films 
5 to 25%w/w 
solution forms 
flexilble films 
It has very good 
film forming 
property. 
Carboxymethylcellul
ose as good film 
formomg property 
Viscosity 
Viscosity of 
various grades 
ranges from 
3mPas-
1,00,000mPas 
75mPas-
6500mPas 
depending 
upon the 
polymer grade 
2%w/v aqueous 
dispersion of 
starch provides 
13mPas 
viscosity 
The viscosity 
(10%w/w,300C)
of  pullulan was 
100 – 180mm2 
4.3-4.7mPas for a 
6.67%w/w 
aqueous solution 
at 600C 
The 1%w/w 
aqueous solution as 
viscosities in the 
range of 5 to 13,000 
mpPas. 
Melting 
point 
Browns at 190 to 
2000 C. Glass 
transition 
temperature is 170 
to 1800C 
It softens at 
1300C ,chars at 
260-2750C 
It decomposes at 
2500C 
1070C  
Browns at 2270C 
chars at 2520C 
 
E. Saliva Stimulating Agent 
A saliva stimulating agent is utilized to enhance the rate of 
production of saliva, because the saliva helps in rapid 
disintegration of fast dissolving film formation. Saliva 
stimulating agents are utilized alone as well as in 
combination between 2 to 6% w/w of the weight of the film9. 
F. Sweetening Agent 
This is the most essential part of the food product or in 
pharmaceutical dosage forms. Natural as well as artificial 
sweetening agents are utilized to improve the palatability of 
the formulation. Sweetening agents commonly used either 
alone or in combination between the concentrations of 3 to 
6%w/w 10. 
G. Flavoring Agent 
Selection of flavor depends on which type of drug is to be 
administered in the formulation. The perception of the oral 
disintegrating / dissolving formulation by an individual, 
depends on the initial flavor quality which is noticed in the 
first few seconds after the product has been absorbed and 
the after taste of the formulation which lasts for at least 
about 10 min. Preferable concentration of flavor 10%w/w 11, 
12, 13. 
H. Surfactant 
Surfactants are utilized as a solubilising or wetting 
dispersing agent so that the film dissolves within seconds 
and release the active agent immediately. 
I. Coloring Agent 
FDA approved coloring agents are used in the manufacturing 
of oral dissolving films. (Not exceeding concentration levels 
of 1%w/w). For example: titanium dioxide. 
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Table 4: Formulating agents of oral dissolving films 
S.No Plasticizers Sweetening agents 
Flavouring 
agents 
Coloring 
agents 
Saliva stimulating 
agents 
Surfactant 
1.  
Aceyl triethyl 
citarate 
Mannitol;sorbitol Lemon Natural Citric acid Polaxamer 407 
2.  
Polyethylene 
glycol 
Xylitol;polyols Peppermint 
Titanium 
oxide 
Lactic acid 
Benzalkoonism 
chloride 
3.  Propylene glycol Aspartame Cinnamon 
Silicon 
dioxide 
Malic acid 
Benzthonium 
chloride 
4.  Sorbitol Glycyrrhizin Vanillin Zinc oxide Ascorbic acid Tweens 
5.  Glycerine Saccharin;cyclamate Menthol  Tartaric acid Spans 
6.  Citrate ester 
Malitol;isomatol 
malitol 
Wintergreen  
Sodium lauryl 
sulphate 
 
7.  Triacetin 
Acesulfame 
potassium 
Orange    
8.  Triethyl citrate Dextrose;fructose Clove    
 
V. Methods used in the manufacture of fast 
dissolving films 
One or combination of the following methods can be used to 
manufacture the mouth dissolving film 17. 
A. Solvent casting 
B. Semisolid casting 
C. Hot melt extrusion 
D. Solid dispersion extrusion 
E. Rolling 
A. Solvent casting method 
In solvent casting method, water soluble polymers are 
dissolved in water and the drug along with other excipients 
are dissolved in applicable solvent and then both the 
solutions are mixed, stirred and finally casted in to the petri 
plate and dried. The specifications are given in table 5. 
 
 
Table 5: Specification condition required by using solvent casting method 
Mixing condition Agitated emulsification 
device 
Vacuum defoaming 
device 
Coating apparatus 
Temp  20-90 0C Flow rate 80L/h Flow rate 80L/h Passage 
time 
2-8min 
Agitating 
time 
40-120 min Agitating time 15min   Drying 
temp 
50-1300C 
Rotating 
speed 
1000-2000 
rpm 
Homogenizer 
pressure 
15min   Solution 
temp 
40-900C 
 
The solvent casting method is given in the flow chart 1. The merits and demerits of the method are given in table 6. 
 
 
 
 
 
                           
                           
 
                               
 
 
                                                   
                                                                      
 
                               
                                     
                                         
Water soluble hydrocolloids dissolved in 
water to form homogenous viscous solution 
Other ingredients including active agents dissolved in 
small portion of aqueous solvent using high shear process 
Both mixtures are mixed to form homogenous viscous solution 
Degassed under vacuum 
Bubble free solution is coated on non-treated casting film 
 
Coated film is sent to aeration drying oven 
Film is cutted in to desired shape and size 
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Table 6: Merits and demerits of solvent casting method 
Merits Demerits 
Great uniformity of thickness. Polymer must be soluble in a volatile solvent or water. 
Great clarity then extrusion. Optimum viscosity should be formed. 
More flexibility.  
Better physical properties.  
Finished film thickness is typically 12-100µm.  
 
B. Semisolid Casting 
In this method a solution of water soluble film forming 
polymer should be prepared and the resulting solution 
should be added to a solution of acid insoluble polymer (e.g. 
cellulose acetate phthalate, cellulose acetate butyrate), which 
was made in ammonium or sodium hydroxide. Then suitable 
amount of plasticizer should be added to form a gel mass. 
Finally, the gel mass should be casted in to the films or 
ribbons using heat controlled drums. The thickness of the 
film formed will be in the rapid of 0.015-0.05 inches. The 
ratio of the acid insoluble polymer to film forming polymer 
must be 1:4 in this method. 
C. Hot Melt Extrusion (HNE) 
In this method, the drug is mixed with carriers in solid form 
and then the extruder having heaters melts the mixture. 
Finally the melt is formed in to films by the dies. There are 
certain benefits of hot melt extrusion 18. 
o It has a fewer operation units. 
o It has better content uniformity. 
o It is an anhydrous process. 
o Hot melt extrusion process is based on polymer with a 
high glass transition temperature such as PVP 14. 
The pharmaceutical challenges of API can be overcome by 
using HME which is given in table 7. 
  
 
Table 7: Determining the pharmaceutical challenges of API by Hot melt extrusion method 
Problem Solution by HME 
Poor bioavailability due to poor API solubility. Enhance dissolution. 
Poor API stability during processing caused by hydrolysis. No hydrolysis. 
Poor taste of the API. Taste-masked dosage form. 
Manufacturing of film. Prepared various type of film such as oral film, buccal film etc. 
 
The advantages and disadvantages of HME are given in table 8. 
Table 8: Advantages and Disadvantages of Hot melt extrusion method 15, 16 
Advantages Disadvantages 
Improved bioavailability of poorly soluble compounds. Thermal process (drug/polymer stability). 
During processing solvents and water are not required. Flow properties of the polymer are necessary to processing. 
Cost-effective process with reduced production time and 
number of unit operations. 
Limited amount of available polymer. 
Better content uniformity was obtained among granules of 
different size ranges. 
Require high power input. 
 The melt technique cannot be applied to heat-sensitive 
materials due to the evaluated temperatures involved. 
 
D.  Solid dispersion extrusion 
In this method immiscible components are ejected with drug 
and then solid dispersions are prepared. Finally the solid 
dispersions are formed in to films by means of dies. 
E. Rolling Method 
In rolling method a solution or suspension having drug is 
rolled on a carrier. The solvent is mainly water and mixture 
of water along with alcohol. The film is dried on the rollers, 
cutted in to desired shapes and sizes. 
VI. Evaluation of Fast Dissolving Films 
A. Thickness: The thickness of film can be determined by 
micrometer screw gauge at different strategic locations 
(at least 5 locations). This is important to determine 
uniformity in the thickness of the film as it is directly 
related to the accuracy of dose in the film. 
B. Dryness Test/Tack Tests: About eight levels of film 
drying process have been identified and they are set-to- 
touch, dust-free, tack-free (surface dry), Dry-to-touch, 
dry-hard, dry-through (dry-to-handle), dry-to-recoat 
and dry print free.  
C. Tensile Strength: Tensile strength is the maximum 
stress in seconds applicable to a point at which the film 
specimen breaks 20. It is measured by the applied load at 
rupture divided by the cross-sectional area of the film as 
given below: 
Where 
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D. Percent Elongation: When stress is applied, a film 
sample stretches and this is indicated to as strain. Strain 
is basically the deformation of film divided by original 
dimension of the sample. As the elongation of film 
increases, the plasticizer content increases 21, 22.  Where              
 
L = Increase in length of film   L0 = Initial length of 
film  
E. Tear Resistance: The maximum stress or force (that is 
meter generally found near the onset of tearing) needed 
to tear the film is noted as the tear resistance value in 
Newton (or pounds-force). 
F. Young's Modulus: Young's modulus or elastic modulus 
is the measure of stiffness of film. It is determined as the 
ratio of applied stress over strain in the region of elastic 
deformation as follows: 
 
Hard and brittle film determines a high tensile strength and 
Young's modulus with small elongation. 
G. Folding Endurance: Folding endurance is 
demonstrated by repeated folding of the film at the 
same place till the film breaks. The number of times the 
film is folded without breaking is reported as the folding 
endurance value 23. 
H. Stickiness Determination: It is determined by texture 
method usually used for measurement of the tack of 
pressure sensitive adhesives. 
I. Swelling Index 24: It is useful in case of film formulation 
having gelling property and determined by two 
methods. 
J. Linear Expansion Coefficient in Water: The film (1 x 1 
cm2) was placed in a petridish and immersed in 10 ml of 
distilled water. Specimens were taken at 30, 40, 60, 80, 
100, 120, 140, 160 and 180 seconds and the size of the 
side length was measured. The linear expansion 
coefficient (L %) was defined as 
 
   Where-   La = Side length after immersion, 
Lb = Side length before immersion 
K. Amount Absorbed: The film is weighed (Wa) and is 
placed in the stainless steel mesh basket. The weight 
after immersion in water is determined (Wc).Similarly 
weight after immersion of basket without film is 
determined (Wc).The amount absorbed (W) is 
determined by following equation: 
 
L. Contact Angle Measurement [25]: Time dependent 
Contact angle is determined by an optical contact angle 
meter. The contact angle determined by different 
methods like the two tangential methods, a height width 
ratio, the circle fitting and sessile drop fitting. It’s 
prediction for wetting behavior, disintegration and 
dissolution of oral films. 
M. Disintegration Time: The disintegration time limit ie: ≤ 
30s for orally disintegrating tablets was described in 
centre for drug evaluation and research (CDER) 
guidance can be applied to fast dissolving oral film. 
Although no official guidance is described for oral fast 
disintegrating films/strips, this may be utilized as a 
qualitative guideline for quality control test or at 
development stage. Pharmacopoeial disintegrating test 
apparatus may be utilized for this study. Typical 
disintegration time for film is 5-30s. 
N. Dissolution Test: Dissolution testing can be operated 
using the standard basket or paddle apparatus 
determined in any of the pharmacopoeia. The volume of 
dissolution medium should be selected as per the sink 
conditions along with highest dose of the API 26. Many 
times the dissolution test can be challenging due to the 
tendency of the film to float onto the dissolution 
medium when the paddle apparatus is employed. So 
mostly we utilize the basket apparatus for evaluation.  
O. Dissolution rate via conductivity: Within one minute, 
the fast dissolving oral films dissolve completely. 
Currently, mostly of the marketed oral films contain 
ionisable components. For greater resolution 
monitoring of the dissolution of fast dissolve oral films, 
they measure conductivity of the dissolution medium. 
P. Assay/Drug content and content uniformity: This is 
calculated by any standard assay method described for 
the particular API in any of the standard pharmacopeia. 
Content uniformity is calculated by estimating the API 
content in the individual film. The content uniformity 
limit was in the range of 85-115%. 
Q. Organoleptic Evaluation: This is important step in 
case of most oral formulations due to its more residence 
time in the oral cavity. The product must possess the 
desired features of sweetness and flavor which is 
acceptable to a large mass of population. For evaluation 
of psychophysical products, special controlled human 
taste panels are utilized. In-vitro methods of utilizing 
taste sensors, specially designed apparatus along with 
drug release by modified pharmacopoeial methods 
being utilized for this purpose 27. Experiments utilizing 
electronic tongue measurements have also been 
reported to distinguish between the sweetness levels in 
taste-masking formulation. 
R. Morphology Studies [28]: Scanning electron microscopy 
(SEM) study specifies the differences between upper 
and lower side of the films. It also helps in 
demonstration of the distribution of API.  Near-infrared 
chemical imaging (NIR-CI) study helps in demonstrating 
the difference between drug distributions in drug 
loaded films and recrystallization. 
VII. Technologies to Produce Films 
A. Soluleaves™ technology is utilized to produce a range of 
oral delivery films that can incorporate active 
ingredients, colours and flavours. Soluleaves™ films can 
be dissolved rapidly on contact with saliva and instantly 
releases the active ingredients and flavours. For 
pharmaceutical uses this method of administration is 
mainly useful for paediatric or elderly patients who may 
have difficulty swallowing traditional tablets or 
capsules. The delivery system can be utilized for the 
cough/cold, gastrointestinal and pain therapeutic areas 
as well as delivering nutritional products. Soluleaves™ 
films can also be designed to attach to mucous 
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membranes and to release the active ingredient slowly 
over 15 minutes. 
B. Wafertab™ is a drug delivery system that administers 
pharmaceutical actives into an ingestible filmstrip. The 
system gives rapid dissolution and release of actives 
when the strip comes into contact with saliva in the 
mouth. The Wafertab™ filmstrip can be flavoured for 
furthermore improved taste masking. The active 
ingredient is accurately dosed and integrated into the 
body of a pre-manufactured Xgel™ film, thus blocking 
the exposure to unnecessary heat and moisture and 
potentially enhancing product stability. The Wafertab™ 
system accommodates itself for many possibilities of 
innovative product design, enabling multiple films with 
different actives to be bonded together. Wafertab™ can 
be processed in a variety of shapes and sizes and it is an 
ideal method for delivery of medicines, which needs fast 
release, or for use by patients who have difficulty in 
swallowing.  
C. Foamburst™ is a distinct variant of the Soluleaves™ 
technology where an inert gas goes into the film during 
production. This concludes in a film with a 
honeycombed structure, which dissolves fastly giving a 
novel mouth sensation. Foamburst™ has intrigued 
interest from food and confectionary manufacturers as a 
means of carrying and releasing flavours. 
D. Xgel™ film is at the centre of Meldex International's 
intellectual property, utilized in all its film systems 
along with its ingestible dosage delivery technologies. 
Xgel™ film gives unique product benefits for healthcare 
and pharmaceutical products, it is non animal- derived, 
accepted on religious grounds and is applicable for 
vegetarians; the film is genetically modified organisms 
(GMO) free and continuous production processing gives 
an economic and competitive manufacturing platform. 
Xgel™ film can be taste masked, coloured, layered, and 
efficient of being enteric properties and also having the 
ability to administer active pharmaceutical ingredients. 
The Xgel™ film systems can be manufactured to 
encapsulate any oral dosage form and also can be 
solubilized in either cold or hot water. Xgel™ film is 
contained of a range of different water-soluble 
polymers, particularly optimised for the intended use. 
VIII. Packaging of the Films:  
The fast dissolving system can be packaged utilizing 
various options, such as single pouch, blister card with 
multiple units, multiple-unit dispenser and continuous 
roll dispenser. There are some patented packaging 
systems for oral film given in the table 9. 
 
Table 9: Oral films containing patented packaging systems 
Packaging Company 
RapidCard Labtec 
Core-peelR Amcor Flexibles 
 
IX. Clinical and Regulatory Aspects:  
In the US Food and Drug Administration, if the product is 
bioequivalent to that of the existing oral product of the drug, 
an Abbreviated New Drug Application (ANDA) route is 
followed. There are no clinical studies related in this generic 
approval process (section 505(j) of the Food, Drug and 
Cosmetics Act). The example of aforementioned case would 
be a comparative bioequivalence between ODT formulation 
and OTF product. However, developed oral film product may 
also display a different target pharmacokinetic profile 
correlated to the existing marketed product. The OTF is 
classified as “new dosage form” and the section 505(b)(2) 
approval process needs to be followed. In this case, a new 
clinical study would be needed. The benefit of a new clinical 
study is that it would award three years of marketing 
exclusivity to the product. In the Europe, Marketing 
Authorization approval (Abridged Application) is important 
as per the European Medicines Evaluation Agency guidelines. 
Either of the two modes i.e. the decentralized procedure or 
the mutual recognition route can be accepted. The Ministry 
of Health, Labor and Welfare is primarily answerable for 
product approvals in Japan. 
 
Table 10: various patents in United States on fast dissolving oral films/strips 
Title 
United States 
Patent 
Issued Inventors Assignee Appl.No Filed 
Fast dissolving orally 
consumable films 
containing a taste 
masking agent 
7,648,712 Jan 19,2010 
Bess; William S. 
(Edison, NJ), 
Kulkarni; Neema 
(Randolph, NJ), 
Ambike; Suhas H. 
(West Hill, CA), 
Ramsay; Michael 
P. (Ajax, CA) 
McNeil-PPC 
(Skillman, NJ) 
11/429,547 May 5, 2006 
Process for 
manufacturing thin film 
strip 
6,824,829 
Nov.30, 
2004 
Nov.30, 2004 Craig 
j.berry 
Aupac 
packaging,inc. 
10/226,451 
Aug.23,2002 
 
Fast dissolving orally 
consumable film 
7,025,983 Apr.11,2006 
Sau Hung Spence 
Leung,Robert S. 
Leone,Lori D. Kumar, 
Neema Kulkarni, 
Albert F. Sorg 
Warner Lambert 
Company LLC. 
09/836,474 Apr.18,2001 
Fast dissolving orally 2003/0208931 Nov. 13, Lori D. Kumar, Warner Lambertv 10/423,398 Apr.25,2003 
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consumable film 
containing the sweetner 
2003 Neema Kulkarni,. 
Albert F. Sorg 
Company LLC. 
 
Fast dissolving film for 
oral administration of 
drugs 
2004/020 Oct.21,2004 
David R.Friend, l 
Aaron W. Levine, 
Kerrie L. Ziegler, 
Emmanuel Manna 
William 
Squire,Esq 
10/744,479 
Dec. 23, 
2003 
 
Fast dissolving orally 
consumable films 
containing a modified 
starch for improved 
heat and moisture 
resistance 
2004/0247648 Dec. 9,2004 
David John Fadden 
Neema Kulkarni, 
Albert F. Sorg 
 
Pfizer, Inc. 
 
10/838,045 
May 3, 2003 
 
Oral fast dissolving film 
for erectile dysfunction 
bioactive agents 
2009/0047330 
Feb. 
19,2009 
Ramesh bangalore _ 12/228702 Oct.9,2008 
Water soluble film for 
oral administration 
with instant wettability 
5,948,430 Sep.7,1999 
Horst George 
Jian Hwa Guo, 
Anthony Serino 
LTS Lohman 
Therapie- 
systeme GmbH 
Zerbe, LTS 
Lohman 
08/904,607 Aug 1,1997 
Water soluble sheet 
composition 
6,800,295 Oct 5,2004 Priscilla S. Fox 
The Dial 
Corporation 
10/267,235 Oct. 9,2002 
Method for producing 
film type dosage 
6,800,329 Oct. 5,2004 
Michael Horstmann, 
Wolfgang Laux, Horst 
Dzekan,Katja 
Zinndorf 
, LTS Lohman 
Therapie- 
systeme AG 
10/314,549 
Dec. 9,2002 
 
Process for 
manufacturing thin film 
strips 
6,824,829 
Nov. 
30,2004 
Craig J. Berry, 
Walter klauser 
Acupac 
packaging,Inc. 
10/226,451 Aug 23,2002 
Flavoured film 7,132,113 Nov.7,2006 
Horst G. Zerbe, 
Fadia Al- Khalil 
Intelgenx Corp. 10/123,142 Apr.16,2002 
Thin film strips 7,241,411 Jul.10,2007 
Craig J. Berry, Walter 
klauser 
Acupac 
packaging,Inc 
10/922,502 Aug.20,2004 
Disintegrable films for 
diagnostic devices 
7,470,397 Dec.30,2008 
William G.Meathrel,  
Nathan A. 
Meyer,Scott 
D.Barnhart,Cathy 
M.Moritz,Andrew 
P.Full,Susan 
R.Newsom, 
Mary Robertson 
Adhesives 
research,inc 
10/970,383 Oct.22,2004 
Film comprising 
nitroglycerine 
20100215774 
August 26, 
2010 
Maibach, Todd _ _ 
February 
8,2008 
Pullulan film 
composition 
7,267,718 Sep.11,2007 
Robert Scott, 
Dominique Cade 
Warner Lambert 
Company LLC. 
10/941,182 
Sep.15,2004 
 
 
 
X. CONCLUSION 
Oral thin films are predetermined for application in the oral 
cavity as they are innovative and promising dosage form 
particularly for use in the pediatrics’ and geriatrics. They 
integrate the greater stability of a solid dosage form and the 
good applicability of a liquid and thus connect the gap 
between two sides and liquid dosage forms into an elegant 
stable and effective delivery vehicle. So they are of great 
significance during the emergency cases such as allergic 
reactions and asthmatic attacks whenever immediate onset 
of action is desired. Today, OTSs are a proven and authorized 
technology for the systemic delivery of APIs for over-the-
counter (OTC) medications and are in the early-to-mid-
development stages for prescription drugs.                 
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